| Completed | Evaluating Public Awareness and Preventive Actions for Dengue Fever in Sudan Amidst Ongoing Crises NCT07205848 | Research and Publication office | — |
| Completed | The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinic NCT06744777 | Khyber Medical University Peshawar | Phase 3 |
| Active Not Recruiting | Efficacy of Fresh Frozen Plasma (FFP) in Treating Thrombocytopenia in Dengue Patients NCT06642493 | Sheikh Hasina National Institute of Burn and Plastic Surgery | N/A |
| Completed | Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults NCT02741128 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients NCT03432442 | Mahidol University | Phase 2 |
| Completed | Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore NCT04048837 | National University Hospital, Singapore | — |
| Terminated | Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subje NCT02992418 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine NCT02948933 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gard NCT02993757 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cerv NCT02979535 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Complet NCT02824198 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects NCT02628444 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedu NCT02623725 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue NCT01943825 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Effi NCT01983553 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India NCT01550289 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vacc NCT01488890 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers NCT01436396 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children NCT01477671 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers NCT01411241 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin Am NCT01374516 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia NCT01373281 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia NCT01254422 | Sanofi | Phase 3 |
| Completed | Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia NCT01134263 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America NCT01187433 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines NCT01064141 | Sanofi | Phase 2 |
| Completed | Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin NCT00993447 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus NCT00919178 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore NCT00880893 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects NCT00875524 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Efficacy and Safety of Dengue Vaccine in Healthy Children NCT00842530 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years NCT00788151 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults NCT00740155 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in th NCT00617344 | Sanofi | Phase 2 |
| Completed | A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children NCT00468858 | U.S. Army Medical Research and Development Command | Phase 2 |
| Completed | Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Again NCT00458120 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects NCT00730288 | Sanofi | Phase 2 |